This is where we write about our work. Methods, targets, assay challenges, drugs, and the science behind binding characterization or formulation development. If you work in biotech or pharma and deal with anything between hit identification, membrane protein targets, antibody or formulation development, you’ll find something useful here.

The topics we cover reflect what we do at 2bind every day. Binding kinetics and what kon and koff tell you beyond a single KD value. Avidity and why it matters for bispecifics and multivalent formats. Hard-to-purify targets like GPCRs and ion channels, and how cell-based methods change what’s measurable. Method selection, when SPR makes sense, when Spectral Shift is the better fit, when neither is enough on its own. Assay development challenges, data quality, and the questions worth asking before you start.

We also write about the broader context. What does early-stage binding data actually contribute to a drug discovery program? What trends are coming up in antibody formulation? Where is the industry going and how does our journey reflect this.